La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
China Resources Pharmaceutical Group Dividende
Dividende contrôle des critères 2/6
China Resources Pharmaceutical Group est une société versant des dividendes avec un rendement actuel de 3.5% qui est bien couvert par les bénéfices.
Informations clés
3.1%
Rendement du dividende
39%
Ratio de distribution
| Rendement moyen de l'industrie | 3.5% |
| Prochaine date de paiement du dividende | n/a |
| Date ex-dividende | n/a |
| Dividende par action | HK$0.184 |
| Résultat par action | HK$0.60 |
| Prévision de rendement du dividende | 3.5% |
Mises à jour récentes des dividendes
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01
China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14Recent updates
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Aug 30China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%
May 13China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17Stabilité et croissance des paiements
Récupération des données sur les dividendes
Dividende stable: Bien que les paiements de dividendes soient restés stables, 3320 verse un dividende depuis moins de 10 ans.
Dividende croissant: Les paiements de dividendes de 3320 ont augmenté, mais la société n'a versé de dividendes que pendant 7 ans.
Rendement des dividendes par rapport au marché
| China Resources Pharmaceutical Group Rendement des dividendes par rapport au marché |
|---|
| Segment | Rendement du dividende |
|---|---|
| Entreprise (3320) | 3.1% |
| 25% du marché (HK) | 3.3% |
| 25% du marché (HK) | 8.1% |
| Moyenne du secteur (Pharmaceuticals) | 3.5% |
| Analyste prévisionnel (3320) (jusqu'à 3 ans) | 3.5% |
Dividende notable: Le dividende de 3320 ( 3.02% ) n'est pas notable par rapport aux 25 % des payeurs de dividendes les plus faibles du marché Hong Kong ( 3.52% ).
Dividende élevé: Le dividende de 3320 ( 3.06% ) est faible par rapport aux 25 % des premiers payeurs de dividendes du marché Hong Kong ( 8.28% ).
Bénéfice distribué aux actionnaires
Couverture des revenus: Avec son taux de distribution relativement faible ( 25.1% ), les paiements de dividendes de 3320 sont bien couverts par les bénéfices.
Paiement en espèces aux actionnaires
Couverture des flux de trésorerie: Avec son faible taux de distribution de dividendes ( 7.7% ), les paiements de dividendes de 3320 sont entièrement couverts par les flux de trésorerie.